Vancouver, British Columbia–(Newsfile Corp. – September 6, 2022) – CVR Medical Corp. (TSXV: CVM) (OTCQB: CRRVF) (“Medical CVR“or the”Company” Where “we“), a Canadian-listed, U.S.-based healthcare company in the medical device market is pleased to announce the completion and filing of its second quarter 2022 financial statements. The financial report is posted on SEDAR.
About CVR Medical
CVR Medical Corp. is a healthcare company that operates in the medical device industry and is focused on the commercialization of its proprietary disruptive device Carotid Stenotic Scan (the “CSS“). The CSS is a diagnostic tool that encompasses subsonic, infrasonic and low frequency sound wave analysis technology. The CSS is a patented device designed to detect and measure carotid arterial stenosis. CVR Medical’s actions are listed on the OTCQX under the symbol “CRRVF”. The Company was previously listed for trading under the symbol “CVM”. Additional information regarding the Company can be found in our recent filings with SEDAR as well as in the information maintained on our website at www.cvrmed.com.
ON BEHALF OF THE COUNCIL:
(signed) Paul Blunden, MD
For more information, contact:
Paul Blunden, MD, President/Director
Email: [email protected]
This press release contains forward-looking information that involves various risks and uncertainties regarding future events relating to: trading and engagement with the Exchange, communications and dealings with CVR Global, engagement with certain advisors, list of terms, the Proposed Restructuring, Definitive Agreement, License Agreement, Review, Certain Corporate and Securities Law Requirements, Capital Raising, 2019 Audit and Potential Litigation. These statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements and are not guarantees of the future performance of the Company. There can be no assurance that any of the events anticipated by the forward-looking statements will occur or, if they occur, what benefits the Company will derive therefrom. These forward-looking statements reflect management’s current beliefs and are based on certain expectations, estimates and assumptions which may prove to be incorrect. A number of risks and uncertainties could cause our actual results to differ materially from those expressed or implied by the forward-looking statements, including: (1) a failure or material setback in negotiations between the Company and CVR Overall ; (2) a failure of the Company to resume trading on the Exchange; (3) a failure of the Company to raise sufficient capital to relaunch the Company; (4) an inability to enter into a definitive agreement with CVR Global; (5) a slowdown in general economic conditions in North America and internationally; (6) the inherent uncertainties and speculative nature associated with the commercialization of technology and the practice of medicine; (7) change in health regulations; (8) any number of events or causes that may delay or stop the commercialization and development of the CSS Device; (9) the risk that the Company will not execute its business plan; (10) the risk of litigation between the Company and certain shareholders and the risk of litigation generally; (11) an inability to retain key employees, (12) an inability to fund operations and growth, (13) compliance with certain requirements of corporate and securities laws; and (14) other factors beyond the Company’s control. These forward-looking statements are made as of the date of this press release and, except as required by law, the Company undertakes no obligation to update these forward-looking statements or to update the reasons why actual results differ. of those projected in the forward-looking statements.
THE TSX VENTURE EXCHANGE INC. HAS NEITHER APPROVED NOR DISAPPROVED THE CONTENT OF THIS PRESS RELEASE. NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATORY SERVICE PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE RELEVANCE OR ACCURACY OF THIS RELEASE.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/136172